Compare Novartis AG (NVS) vs T-Mobile Us Inc (TMUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs T-Mobile Us Inc — how do they compare? Novartis AG trades at $143.75 (market cap $268.57B), while T-Mobile Us Inc trades at $148.58 (market cap $183.76B). The key difference: Novartis AG is the larger of the two by market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and T-Mobile Us Inc for 84 Days on average.
| NVS | TMUS | |
|---|---|---|
Market Cap | $268.57B | $183.76B |
Volume | 1,532,573 | 4,294,650 |
Sector | Health | Media |
52-Week High | $168.62 | $230.06 |
52-Week Low | $121.80 | $148.58 |
Typical Hold Time | 82 Days | 84 Days |
Enterprise Value | $309.89B | $300.37B |
Dividend Yield | 3.31% | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVS trades at $143.11, down 0.12% on the day, with a bearish technical signal and mixed earnings history including a recent Q1 2026 miss. The company maintains strong profitability with a 22.5% net income margin and 30.55% ROE, while recent news highlights a major $7.8B licensing deal with China's Abogen and ongoing investor scrutiny following clinical trial setbacks.
The outlook is cautious; analyst consensus is a Hold with a $146 price target, but risks include pipeline disappointments and M&A execution. Upside hinges on successful drug launches and deal integration, while downside stems from competitive pressures and regulatory challenges.
TMUS trades at $171.31, up 2.2% today, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $88.31B in 2025, with a net income margin of 11.45%, while the company announced a 15% dividend hike and AI-driven 5G network enhancements. Analyst consensus is strongly bullish with a $231.10 price target, though debt levels and competitive pressures remain considerations.
The outlook for TMUS is positive, driven by robust cash flow, strategic investments in network resilience, and favorable analyst sentiment. Key risks include high debt exposure and industry competition, but strong fundamentals and growth initiatives support a constructive view for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About T-Mobile Us Inc
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →
